Skip to content
Open access

Case report: autoimmune encephalitis associated with ovarian teratoma in a young patient

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Case Presentation: We report a 14-year-old female patient with acute confusion, behavioral changes, headache and fever, progressing to status epilepticus. Initial investigation with brain computed tomography revealed no abnormalities. Cerebrospinal fluid (CSF) analysis revealed lymphocytic pleocytosis (112 cells/mm³, 97% lymphocytes), hypoglycorrhachia (CSF/serum glucose ratio 0.46) and elevated opening pressure (30 cmH₂O). Electroencephalography demonstrated extreme delta brush, a characteristic pattern of anti-NMDA receptor encephalitis. Paraneoplastic screening revealed an ovarian teratoma, which was surgically removed. The patient received methylprednisolone pulse therapy (1 g/day for 5 days) and empirical acyclovir until infectious causes were excluded, followed by plasmapheresis and intravenous immunoglobulin (2 g/kg over 5 days). Due to the lack of clinical improvement, second-line therapy with rituximab was initiated. Despite early recognition, after six weeks the patient remained with severe neurological impairment (Glasgow Coma Scale score of 6), necessitating tracheostomy and mechanical ventilation, in addition to presenting with severe orofacial and limb dyskinesias, requiring symptomatic management. Autoantibody results were pending. Discussion: Anti-NMDA receptor encephalitis is the most common form of autoimmune encephalitis, with an estimated incidence of 1.5 per 1,000,000 individuals per year. It is of significant clinical importance due to the risk of misdiagnosis as infectious encephalitis and its potential to cause neurological sequelae. The disease predominantly affects young females (median age 21, male/female ratio of 1:4) and is commonly associated with tumors, particularly ovarian teratomas. Clinically, it presents with acute or subacute neuropsychiatric symptoms, followed by seizures and movement disorders, with dyskinesias occurring in most patients (75%). First-line treatment includes plasmapheresis and/or intravenous immunoglobulin, without clear superiority between approaches. In cases of poor clinical response, second-line therapies such as rituximab or cyclophosphamide should be promptly initiated. Despite its severity, the prognosis is generally favorable, with approximately 80% of cases progressing to neurological recovery over weeks to months. Final Comments: Autoimmune encephalitis encompasses a broad clinical spectrum, and its complexity necessitates individualized evaluation. The understanding of its pathophysiology is relatively recent, with the identification of pathogenic autoantibodies and advances in immunobiological therapies representing significant progress over the past two decades. However, increased awareness among non-specialist physicians is still needed to prevent delays in referral to specialized care and timely initiation of treatment. Furthermore, improving access to diagnostic testing for autoantibodies is essential to enable more effective treatment strategies and to reduce disease-related morbidity and mortality.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.